Imaging surrogate end points in heart failure trials.


Journal Article (Review)

Despite the epidemiologic importance, large investments, and careful design, recent results of heart failure (HF) trials have been unable to demonstrate significant treatment improvements. This shortcoming has led to a reassessment of research methodology, particularly related to sample size and costs, for which end-point selection is a main issue. In comparing interventions in clinical trials, surrogate end points may be used to reduce the costs. To this end, ongoing research into the roles of imaging biomarkers as reliable surrogate end points may lead to better clinical trial design and more efficient development of new therapies for HF.

Full Text

Duke Authors

Cited Authors

  • Bettari, L; Borges-Neto, S

Published Date

  • October 2011

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 509 - 518

PubMed ID

  • 21925434

Pubmed Central ID

  • 21925434

International Standard Serial Number (ISSN)

  • 1551-7136

Digital Object Identifier (DOI)

  • 10.1016/j.hfc.2011.06.008


  • eng

Conference Location

  • United States